α-Adrenergic receptor regulation of skeletal muscle blood flow during exercise in heart failure patients with reduced ejection fraction

Am J Physiol Regul Integr Comp Physiol. 2019 May 1;316(5):R512-R524. doi: 10.1152/ajpregu.00345.2018. Epub 2019 Feb 21.

Abstract

Patients suffering from heart failure with reduced ejection fraction (HFrEF) experience impaired limb blood flow during exercise, which may be due to a disease-related increase in α-adrenergic receptor vasoconstriction. Thus, in eight patients with HFrEF (63 ± 4 yr) and eight well-matched controls (63 ± 2 yr), we examined changes in leg blood flow (Doppler ultrasound) during intra-arterial infusion of phenylephrine (PE; an α1-adrenergic receptor agonist) and phentolamine (Phen; a nonspecific α-adrenergic receptor antagonist) at rest and during dynamic single-leg knee-extensor exercise (0, 5, and 10 W). At rest, the PE-induced reduction in blood flow was significantly attenuated in patients with HFrEF (-15 ± 7%) compared with controls (-36 ± 5%). During exercise, the controls exhibited a blunted reduction in blood flow induced by PE (-12 ± 4, -10 ± 4, and -9 ± 2% at 0, 5, and 10 W, respectively) compared with rest, while the PE-induced change in blood flow was unchanged compared with rest in the HFrEF group (-8 ± 5, -10 ± 3, and -14 ± 3%, respectively). Phen administration increased leg blood flow to a greater extent in the HFrEF group at rest (+178 ± 34% vs. +114 ± 28%, HFrEF vs. control) and during exercise (36 ± 6, 37 ± 7, and 39 ± 6% vs. 13 ± 3, 14 ± 1, and 8 ± 3% at 0, 5, and 10 W, respectively, in HFrEF vs. control). Together, these findings imply that a HFrEF-related increase in α-adrenergic vasoconstriction restrains exercising skeletal muscle blood flow, potentially contributing to diminished exercise capacity in this population.

Keywords: blood flow; exercise; heart failure; neurohumoral; sympathetic.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adrenergic Antagonists / administration & dosage
  • Aged
  • Arteries / innervation*
  • Blood Flow Velocity
  • Case-Control Studies
  • Exercise Tolerance* / drug effects
  • Female
  • Heart Failure / diagnosis
  • Heart Failure / metabolism
  • Heart Failure / physiopathology*
  • Humans
  • Lower Extremity
  • Male
  • Middle Aged
  • Muscle Contraction
  • Muscle, Skeletal / blood supply*
  • Receptors, Adrenergic, beta-1 / metabolism*
  • Regional Blood Flow
  • Stroke Volume*
  • Sympathetic Nervous System / drug effects
  • Sympathetic Nervous System / metabolism
  • Sympathetic Nervous System / physiopathology*
  • Time Factors
  • Vasoconstriction* / drug effects
  • Vasodilation
  • Ventricular Function, Left*

Substances

  • ADRB1 protein, human
  • Adrenergic Antagonists
  • Receptors, Adrenergic, beta-1